Levodopa/Carbidopa Neuraxpharm

Levodopa, the active ingredient in Levodopa/Carbidopa Neuraxpharm, is a dopamine precursor combined with a peripheral aromatic L‑amino acid decarboxylase inhibitor presented as an oral tablet formulation for oral use. It is indicated for the management of Parkinson's disease and related parkinsonian syndromes in adults. GNH USA supplies Levodopa/Carbidopa Neuraxpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levodopa/Carbidopa acts on the dopaminergic pathway to improve motor function in Parkinsonian disorders. - Parkinson's disease: improves bradykinesia, rigidity and tremor, enhancing daily activities. - Parkinsonian syndrome: alleviates motor deficits in secondary parkinsonism caused by drugs or vascular disease. - Motor fluctuations in Parkinson's disease: reduces OFF periods and prolongs ON time, helping maintain consistent symptom control.

Levodopa/Carbidopa may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or other psychiatric disturbances - Severe hypotension or arrhythmias - Neuroleptic malignant‑like syndrome - Hyperpyrexia with muscle rigidity

Before initiating therapy, clinicians should consider several safety measures. - Dose titration: start low and increase gradually to minimize adverse effects. - Monitor blood pressure: risk of orthostatic hypotension, especially in the elderly. - Assess renal and hepatic function: adjust dosing if significant impairment is present. - Avoid abrupt discontinuation: sudden withdrawal may worsen motor symptoms. - Pregnancy and lactation: use only if potential benefit justifies potential risk to the fetus or infant. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Levodopa/Carbidopa can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may precipitate hypertensive crisis. - Anticholinergic agents: can diminish levodopa efficacy. - High‑protein meals: may impair levodopa absorption and reduce clinical response.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase levodopa plasma levels. - Antihypertensive drugs: additive effect on blood pressure, increasing risk of hypotension. - Iron or calcium supplements: can bind levodopa in the gut, reducing its bioavailability.